Irritable Bowel Syndrome (IBS) is a chronic, functional gastrointestinal disorder that affects approximately 10–15% of the global population and imposes a significant burden on healthcare systems and patients’ quality of life. Characterized by abdominal pain and altered bowel habits in the absence of structural abnormalities, IBS is now increasingly recognized as a multifactorial condition involving gut-brain axis dysregulation, motility disturbances, visceral hypersensitivity, microbial dysbiosis, and immune activation. Among the most modifiable and impactful contributors to symptom generation is diet. This review explores the evolving understanding of dietary influences on IBS pathophysiology and presents a comprehensive summary of evidence-based nutritional interventions. Traditional and emerging dietary strategies—including low FODMAP, gluten-free, fiber-modulated, and lactose/fructose-restricted diets—are assessed for their clinical efficacy and mechanistic insights. Functional food approaches, such as the use of probiotics, prebiotics, peppermint oil, polyphenols, and low-histamine diets, are also discussed for their therapeutic potential. The review further addresses the integration of personalized nutrition, highlighting the controversial role of food sensitivity testing and the promise of nutrigenomics. It also underscores the importance of combining dietary therapy with lifestyle factors like stress management, physical activity, and cognitive-behavioral support. Clinical guidelines from leading global organizations are reviewed to guide evidence-based practice. In summary, dietary management in IBS is no longer one-size-fits-all but must be individualized, evidence-driven, and holistic. Future research should prioritize long-term outcomes, microbiome-targeted therapies, and precision nutrition

Understanding Irritable Bowel Syndrome: Definition, Impact, and Dietary Relevance

Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain or discomfort associated with altered bowel habits in the absence of identifiable structural pathology. IBS is clinically subtyped into four categories based on predominant stool patterns: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed-type (IBS-M), and unsub typed (IBS-U) when bowel habits do not meet criteria for the other subtypes (Mearin et al., 2016). Globally, IBS affects approximately 11.2% of the population, with regional variations ranging from 7% in South Asia to 21% in South America (Oka et al., 2020). This widespread prevalence translates into a significant socioeconomic burden, with IBS patients showing higher rates of work absenteeism, decreased productivity, and increased healthcare utilization. For example, in the United States alone, IBS is estimated to cost over $20 billion annually in direct and indirect expenses (Peery et al., 2012). The pathophysiology of IBS is multifactorial, involving altered gut-brain axis communication, visceral hypersensitivity, dysbiosis, low-grade inflammation, and psychological comorbidities such as anxiety and depression (Ford et al., 2020). Diet has emerged as a critical modifiable factor in IBS management, influencing symptom severity and gut microbiota composition. Up to 84% of IBS patients report symptom exacerbation after meals, particularly following consumption of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) (Halmos et al., 2014). Consequently, dietary strategies, especially low-FODMAP diets, are increasingly recommended in clinical practice to alleviate IBS symptoms. The aim of this review is to explore the role of diet in the pathogenesis and management of IBS, examining current scientific evidence and highlighting emerging nutritional therapies.

The thyroid gland, a butterfly-shaped endocrine organ located at the base of the neck, plays a central role in regulating metabolic processes, growth, and development. Its optimal function is vital for physiological homeostasis, and disruptions can lead to significant clinical conditions.

2.1 Thyroid Gland Function and Hormone Regulation

The thyroid gland synthesizes two main hormones: thyroxine (T4) and triiodothyronine (T3), both of which are critical regulators of metabolism. The secretion of these hormones is tightly regulated by the hypothalamic-pituitary-thyroid (HPT) axis. Thyrotropin-releasing hormone (TRH) from the hypothalamus stimulates the anterior pituitary to release thyroid-stimulating hormone (TSH), which in turn prompts the thyroid gland to produce T3 and T4 (Brent, 2012).

Approximately 80% of the hormone released by the thyroid is T4, which is later converted to the more active T3 in peripheral tissues. Feedback inhibition from circulating T3 and T4 levels helps maintain hormonal balance. Disruption in this axis, whether at the level of the hypothalamus, pituitary, or thyroid, can result in hypo- or hyperthyroidism (Yen, 2001).

2.2 Impact of Lifestyle Factors on Endocrine Function

Stress and the HPA Axis: Chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis, elevating cortisol levels, which can suppress TSH secretion and hinder peripheral conversion of T4 to T3. Long-term stress is associated with altered thyroid hormone levels and may precipitate autoimmune thyroid conditions (Peters et al., 2017).

Sleep and Circadian Rhythm: Disrupted circadian rhythms can influence the pulsatile release of TSH. Studies show that night-shift workers exhibit altered thyroid profiles, often displaying elevated TSH and reduced T3 levels (Srinivasan et al., 2019).

Physical Activity and Metabolism: Moderate exercise enhances thyroid function, promoting T3 production and metabolic efficiency. Conversely, excessive exercise or energy restriction can lower T3 levels, mimicking hypothyroidism (Hackney et al., 2012).

                                                                                                 Table 1: Lifestyle Factors Influencing Thyroid Function

2.3 Overview of Common Thyroid Disorders

Hypothyroidism: Characterized by insufficient thyroid hormone production, it can result from iodine deficiency, autoimmune destruction (Hashimoto’s thyroiditis), or post-surgical causes. Symptoms include fatigue, weight gain, cold intolerance, and depression. Hashimoto’s is the most common cause in developed nations and is marked by elevated TSH and low free T4, along with thyroid peroxidase (TPO) antibodies (Vanderpump, 2011).

Hyperthyroidism: Excess thyroid hormone production leads to symptoms like weight loss, anxiety, tachycardia, and heat intolerance. Graves’ disease is the predominant autoimmune etiology, identifiable by TSH receptor antibodies (TRAb), suppressed TSH, and elevated T3 and T4 (Smith & Hegedüs, 2016).

Thyroid Nodules and Cancer: Nodules are prevalent, detected in up to 50% of the population via ultrasound. Most are benign, but a small fraction may harbor malignancy. Papillary thyroid carcinoma is the most common form, with excellent prognosis when detected early (Haugen et al., 2016).

                                                                                                   Table 2: Common Thyroid Disorders at a Glance

The gastrointestinal symptoms of irritable bowel syndrome (IBS)—such as bloating, abdominal pain, diarrhea, and constipation—are frequently associated with specific dietary triggers. Patients often report a strong relationship between food intake and symptom exacerbation, with up to 84% noting that certain foods provoke symptoms (Böhn et al., 2013). 

3.1 High-FODMAP Foods FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) are short-chain carbohydrates poorly absorbed in the small intestine. They undergo rapid fermentation by colonic bacteria, producing gas and drawing water into the gut, leading to distension and discomfort (Halmos et al., 2015).

3.2 Fatty Foods Dietary fats delay gastric emptying and enhance colonic contractions, particularly in IBS-D patients. High-fat meals exacerbate symptoms like bloating and urgency due to hypersensitivity of the gastrointestinal tract (Simrén et al., 2007). 

3.3 Gluten and Wheat Sensitivity Many IBS patients without celiac disease report symptom improvement on a gluten-free diet. Non-celiac gluten sensitivity may involve immune activation or altered gut permeability. However, recent 

studies suggest that fructus in wheat may be the true culprits rather than gluten itself (Biesiekierski et al., 2013). 

3.4 Caffeine and Alcohol Caffeine stimulates gastric acid and colonic motility, aggravating diarrhea in sensitive individuals. Alcohol, particularly beer and wine, can irritate the gut lining and disturb motility, especially in combination with other triggers (Rao et al., 2014). 

3.5 Spicy Foods Capsaicin, the active component in spicy foods, activates TRPV1 receptors involved in pain transmission. Frequent intake may increase visceral hypersensitivity and exacerbate abdominal discomfort (Yazdanpanah et al., 2021). 

3.6 Artificial Sweeteners Polyols such as sorbitol, mannitol, and xylitol are poorly absorbed and fermented in the colon, contributing to bloating, flatulence, and diarrhea. These are especially problematic in sugar-free gums and diet beverages (Tuck et al., 2014). 

3.7 Fiber Type and Quantity Fiber have a dual role. Soluble fiber (e.g., psyllium) improves stool consistency and reduces symptoms. In contrast, insoluble fiber (e.g., wheat bran) may worsen bloating and discomfort due to increased mechanical irritation (Moayyedi et al., 2014).

                                                                                                            Table 3: Common Dietary Triggers in IBS

4.1 Low FODMAP Diet 4.1.1 Mechanism of Action 

This diet reduces intake of poorly absorbed fermentable carbohydrates, thereby minimizing luminal distension and associated symptoms.

4.1.2 Phases

1. Elimination Phase: 2–6 weeks of strict low-FODMAP intake.
2. Reintroduction Phase: Gradual testing of individual FODMAP groups.
3. Personalization Phase: Creating a sustainable long-term plan.

4.1.3 Clinical Evidence and Efficacy A randomized controlled trial by Staudacher et al. (2017) showed that 76% of patients reported symptom relief with a low-FODMAP diet. 

4.1.4 Limitations and Risks Potential risks include reduced prebiotic fiber intake and altered gut microbiota composition. Dietitian supervision is recommended. 4.2 Gluten-Free Diet 4.2.1 Non-Celiac Gluten Sensitivity (NCGS) Some IBS patients show gluten-responsive symptoms despite negative celiac tests. 

4.2.2 Efficacy Biesiekierski et al. (2013) found symptom improvement in up to 50% of IBS patients on a gluten-free diet, though fructans may be responsible for symptoms in many cases. 

4.2.3 Controversies Distinguishing between gluten sensitivity and FODMAP intolerance is challenging due to overlapping content in wheat-containing foods. 

4.3 Fiber Modulation 

4.3.1 Soluble Fiber Psyllium has been shown to improve symptoms in IBS-C and IBS-M. Moayyedi et al. (2014) observed a significant reduction in global IBS symptoms with psyllium supplementation. 

4.3.2 Insoluble Fiber Wheat bran may worsen symptoms due to its roughage effect and limited fermentability. 

4.3.3 Guidelines ACG recommends soluble fiber as first-line treatment, while insoluble fiber is generally discouraged. 

4.4 Lactose and Fructose Restriction 

4.4.1 Prevalence of Intolerance Lactose and fructose malabsorption are reported in 20–40% of IBS patients (Misselwitz et al., 2013). 

4.4.2 Diagnostic Strategies Hydrogen breath testing aids diagnosis, followed by individualized dietary restriction.

                                                                                            Table 4: Efficacy of Dietary Interventions in IBS

A growing body of evidence supports novel dietary strategies for managing IBS beyond the traditional low-FODMAP and fiber-modulated diets. These include probiotics, prebiotics, peppermint oil, polyphenols, and low-histamine diets—all of which offer potential in reducing symptoms by targeting the microbiome, inflammation, gut motility, or visceral sensitivity.

5.1 Probiotics and Prebiotics

5.1.1 Specific Strains Clinical trials suggest that specific strains of Bifidobacterium and Lactobacillus offer symptom relief in IBS patients. Bifidobacterium infantis 35624 and Lactobacillus plantarum 299v are among the most studied, with evidence showing improvement in bloating, pain, and stool regularity (Whorwell et al., 2006; Nobaek et al., 2000).

5.1.2 Mechanisms and Clinical Trials Probiotics modulate intestinal barrier function, produce short-chain fatty acids, reduce mucosal inflammation, and alter the gut-brain axis. A meta-analysis reported that multi-strain probiotics reduced global IBS symptoms in 21–75% of participants across studies (Ford et al., 2018). Prebiotics like galacto-oligosaccharides (GOS) promote beneficial microbial growth but may initially cause bloating. Emerging synbiotics—combinations of pro- and prebiotics—are under evaluation for synergistic effects (Wilson et al., 2020). 

5.2 Peppermint Oil 

5.2.1 Antispasmodic Properties Peppermint oil contains menthol, a calcium channel blocker that reduces smooth muscle contraction in the gastrointestinal tract. This makes it a potent natural antispasmodic. 

5.2.2 Clinical Efficacy and Dosage Multiple randomized controlled trials confirm its efficacy. A pooled analysis showed that enteric-coated peppermint oil capsules significantly reduced IBS symptoms in 44–79% of patients (Cash et al., 2016). Typical dosage is 180–225 mg, taken up to three times daily before meals. 

5.3 Polyphenols and Anti-Inflammatory Diets 

5.3.1 Role in Gut Barrier Integrity Polyphenols such as curcumin (turmeric), epigallocatechin gallate (EGCG, green tea), and anthocyanins (berries) improve mucosal barrier integrity, reduce oxidative stress, and modulate gut microbial composition (Cardona et al., 2013). 

5.3.2 Sources and Dietary Patterns Anti-inflammatory diets rich in plant polyphenols show promise. For example, the Mediterranean diet, abundant in polyphenol-rich foods, has been associated with reduced IBS severity scores (Papada et al., 2018).

5.4 Low-Histamine Diet and Mast Cell Modulation 

5.4.1 Emerging Evidence Some IBS patients exhibit mast cell activation and elevated histamine levels in gut mucosa. Histamine-rich foods (e.g., fermented foods, alcohol, aged cheese) may worsen symptoms (Theoharides et al., 2015). 5.4.2 Practical Implications Low-histamine diets may benefit a subset of IBS sufferers. However, more clinical trials are needed. A trial by Schnedl et al. (2021) reported significant symptom reduction in patients adhering to low-histamine protocols for four weeks.

                                                                                       Table 5: Functional Foods and IBS - Evidence Overview

Emerging tools like nutrigenomics allow a more tailored dietary approach. Genetic polymorphisms (e.g., in the FUT2 gene affecting microbiota) may predict dietary responsiveness. Although promising, these methods are still under validation (Mills et al., 2019). Food sensitivity tests (e.g., IgG, MRT) remain controversial due to limited reproducibility and lack of robust evidence. Despite this, some patients report subjective improvements with IgG-guided elimination diets (Atkinson et al., 2004). Personalized elimination diets, guided by symptom diaries and professional support, remain the gold standard. Registered dietitians play a key role in ensuring nutritional adequacy and helping patients navigate complex dietary regimens.

7. Lifestyle Integration with Diet

Managing IBS requires a holistic approach. Chronic stress influences gut function via the HPA axis and vagal tone. CBT and gut-directed hypnotherapy can improve IBS outcomes by modifying cognitive and emotional responses to symptoms (Laird et al., 2016). Physical activity improves gut motility and reduces stress-related symptom flare-ups. Regular aerobic exercise has shown to improve symptoms in 60% of patients in RCTs (Johannesson et al., 2015). Sleep quality correlates with symptom severity. Sleep deprivation can worsen pain perception and gut inflammation (Jarrett et al., 2008). Sleep hygiene practices form a supportive pillar in IBS care.

8. Clinical Guidelines and Consensus Statements

• ACG (2021): Recommends low-FODMAP as first-line for refractory IBS and supports peppermint oil and probiotics with moderate evidence.
• NICE (2017): Encourages food diaries, routine fiber advice, and low-FODMAP diet if general advice fails.
• WGO: Advocates global application of evidence-based dietary strategies with local adaptability.
• Rome IV Criteria: Emphasize individualized, biopsychosocial care plans integrating dietary and psychological interventions

                                                                                                     Table 6: Clinical Recommendations by Key Organizations

The landscape of dietary management in irritable bowel syndrome (IBS) has shifted from generalized advice to highly individualized, scientifically supported interventions. Key findings from the literature reveal that diet plays a pivotal role not only in symptom modulation but also in influencing the core pathophysiological mechanisms of IBS, including microbial composition, immune activation, motility, and visceral sensitivity. The low FODMAP diet currently holds the strongest evidence base, with substantial clinical benefits for a majority of patients. However, it is not without its limitations, particularly concerning long-term sustainability and potential effects on gut microbiota diversity. Other dietary approaches, such as gluten-free and fiber-modulated diets, show benefit in selected individuals. Additionally, the use of probiotics, peppermint oil, polyphenols, and low-histamine diets highlights the expanding frontier of functional food-based therapy in IBS management. Personalized nutrition, supported by symptom tracking and guided by dietitians, remains the cornerstone of sustainable outcomes. While tools such as food sensitivity testing and nutrigenomic profiling offer future promise, their clinical utility is still evolving. Moreover, the integration of dietary strategies with lifestyle modifications—especially stress reduction, improved sleep, and psychological support—emphasizes the need for a multidisciplinary model of care. Clinical guidelines from major gastrointestinal organizations increasingly endorse dietary therapies as a core component of IBS management. Moving forward, robust clinical trials, long-term safety assessments, and microbiome-based diagnostics will be essential in refining therapeutic strategies. Ultimately, a personalized, evidence-informed, and patient-centered approach remains the optimal pathway for effective and compassionate IBS care.

Funding: None

Conflict of interest: None